Comparative Pharmacology
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE versus QVAR REDIHALER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE versus QVAR REDIHALER.
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE vs QVAR REDIHALER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelastine is a histamine H1-receptor antagonist that inhibits histamine release from mast cells; fluticasone propionate is a corticosteroid that suppresses inflammatory mediators including cytokines, prostaglandins, and leukotrienes, reducing nasal inflammation.
Beclomethasone dipropionate is a prodrug that is hydrolyzed by esterases to the active metabolite beclomethasone-17-monopropionate (17-BMP). 17-BMP is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to modulation of gene expression involved in inflammatory pathways, including inhibition of pro-inflammatory cytokines, reduction of eosinophil survival and migration, and suppression of mast cell mediators.
1 spray per nostril twice daily (137 mcg azelastine hydrochloride and 50 mcg fluticasone propionate per spray).
Inhalation: 40-80 mcg twice daily; maximum 320 mcg twice daily.
None Documented
None Documented
Azelastine: ~25 hours (range 22-27 h). Fluticasone propionate: ~7.8 hours intranasal; 7-8 hours IV; context: intranasal dosing achieves steady-state in 1-2 weeks.
1.5-2.0 hours (terminal half-life) after inhalation; supports twice-daily dosing.
Azelastine: 75% renal (as unchanged drug and metabolites), 25% fecal. Fluticasone propionate: primarily fecal after IV (90%), renal <5%; after intranasal, significant first-pass hepatic metabolism to inactive metabolites excreted in bile and feces.
Primarily hepatic metabolism via CYP3A4; metabolites are excreted in feces (~64%) and urine (~12%).
Category A/B
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid